- Home
- ODD vs LGND Comparison
ODD vs LGND Comparison
Compare ODD & LGND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ODD
- LGND
- Stock Information
- Founded
- ODD 2018
- LGND 1987
- Country
- ODD Israel
- LGND United States
- Employees
- ODD N/A
- LGND N/A
- Industry
- ODD
- LGND Biotechnology: Pharmaceutical Preparations
- Sector
- ODD
- LGND Health Care
- Exchange
- ODD Nasdaq
- LGND Nasdaq
- Market Cap
- ODD 2.7B
- LGND 2.3B
- IPO Year
- ODD 2023
- LGND 1992
- Fundamental
- Price
- ODD $48.39
- LGND $120.43
- Analyst Decision
- ODD Buy
- LGND Strong Buy
- Analyst Count
- ODD 7
- LGND 6
- Target Price
- ODD $53.29
- LGND $145.00
- AVG Volume (30 Days)
- ODD 462.7K
- LGND 107.6K
- Earning Date
- ODD 11-06-2024
- LGND 11-07-2024
- Dividend Yield
- ODD N/A
- LGND N/A
- EPS Growth
- ODD 80.44
- LGND 160.46
- EPS
- ODD 1.64
- LGND 2.47
- Revenue
- ODD $620,646,000.00
- LGND $152,422,000.00
- Revenue This Year
- ODD $27.40
- LGND $26.86
- Revenue Next Year
- ODD $20.03
- LGND $13.16
- P/E Ratio
- ODD $29.45
- LGND $48.80
- Revenue Growth
- ODD 29.59
- LGND N/A
- 52 Week Low
- ODD $30.34
- LGND $67.53
- 52 Week High
- ODD $51.00
- LGND $129.90
- Technical
- Relative Strength Index (RSI)
- ODD 57.86
- LGND 52.94
- Support Level
- ODD $46.32
- LGND $113.39
- Resistance Level
- ODD $50.72
- LGND $124.03
- Average True Range (ATR)
- ODD 2.26
- LGND 5.31
- MACD
- ODD 0.13
- LGND -0.50
- Stochastic Oscillator
- ODD 64.30
- LGND 48.65
About ODD ODDITY Tech Ltd.
ODDITY Tech Ltd offers a consumer tech platform that is built to transform the beauty and wellness market. The ODDITY platform is designed to support a portfolio of brands and services that innovate and disrupt the expansive beauty and wellness market. It consumes user data to develop physical beauty and wellness products that deliver performance and functionality. Its brands include SpoiledChild and IL Makiage.
About LGND Ligand Pharmaceuticals Incorporated
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.